Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
GH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.14 - $52.92
Previous CloseN/A
Volume639.07K
Average Volume (3M)2.39M
Market Cap
$5.92B
Enterprise Value$5.78B
Total Cash (Recent Filing)$698.57M
Total Debt (Recent Filing)$1.31B
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Jul 31, 2025EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding123,888,050
10 Day Avg. Volume1,939,319
30 Day Avg. Volume2,390,916
Financial Highlights & Ratios
PEG Ratio-2.60
Price to Book (P/B)-20.61
Price to Sales (P/S)0.00
P/FCF Ratio-16.95
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue2.03
Enterprise Value/Gross Profit12.17
Enterprise Value/Ebitda-3.40
Forecast
1Y Price Target
$60.71Price Target Upside25.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Guardant Health News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company raised its 2025 revenue guidance due to broad-based outperformance and foresees strong growth in Oncology revenue.
Market AdoptionShield has been included in NCCN colorectal screening guidelines, which is expected to help drive community adoption and commercial payor reimbursement.
Regulatory ApprovalShield MCED received a Breakthrough Device designation from the FDA, highlighting its potential impact in the diagnostics market.
Bears Say
Competitor ActivityUpcoming blood-based colorectal cancer screening data from a competitor may cause a near-term overhang for Guardant Health shares.
Performance ConcernsThe performance of the Shield MCD assay could degrade with a larger pivotal and registrational trial, as observed with other screening assays.
Product SensitivityShield's AA sensitivity of 13% is lower than other recommended colorectal screening modalities.
Ownership Overview
3.98% Insiders
26.66% Mutual Funds
38.36% Other Institutional Investors
12.58% Public Companies and Individual Investors
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $20.14 and its highest was $52.92 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $5.92B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Jul 31, 2025 which is in 55 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Apr 30, 2025. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.76 by -$0.01.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.72.
How many shares outstanding does Guardant Health have?
Guardant Health has 123,888,050 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.76. Following the earnings report the stock price went up 3.472%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.71 (25.41% Upside)
$60.71 (25.41% Upside)
Blogger Sentiment
Bullish
GH Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $355.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.21%
12-Months-Change
Fundamentals
Return on Equity
-4584.47%
Trailing 12-Months
Asset Growth
-21.14%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
GH Company Deck
GH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment with strong revenue growth across multiple segments, gross margin improvements, and raised full-year guidance. However, challenges such as high cash burn and limited commercial payer reimbursement for Shield were noted.Read More>GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
GH Stock 12 Month Forecast
Average Price Target
$60.71
▲(25.41%Upside)